Bio Protocol has successfully raised $6.9 million in a seed funding round led by Arthur Hayes’ Maelstrom Fund, with participation from notable venture firms such as Mechanism Capital, Animoca Brands, and others. This funding round coincides with the launch of Bio V2, an upgraded platform designed to foster onchain scientific innovation through decentralised AI agents called BioAgents.
The platform aims to revolutionise scientific research by allowing researchers to convert their work into BioAgents, which can generate hypotheses, streamline research processes, and attract funding through token sales. This model aligns with the decentralised science movement, leveraging blockchain technology to democratise access to research funding and collaboration.
Bio’s first flagship BioAgent, Aubrai, developed in collaboration with VitaDAO and Dr. Aubrey de Grey, has already made significant strides, minting over 1,000 hypotheses and raising $250,000 in research funding. The success of Aubrai has positioned Bio as a promising platform for tokenised scientific research.
The recent launch of Bio V2 introduced new features such as Ignition Sales for rapid BioAgent launches, the BioXP Rewards system for research contributions, and staking options to enhance liquidity and engagement. Additionally, projects within Bio’s ecosystem are advancing towards clinical milestones, with significant funding directed to labs worldwide.
With the secured funding, Bio plans to expand its BioAgent framework globally, aiming to drastically reduce drug discovery and development timelines, potentially transforming the future of medicine. Despite market fluctuations, the growing interest from venture firms and researchers underscores the potential of decentralised science as a new frontier for innovation.
